Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an…
Biotechnology
US, San Diego [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Crinetics Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2018 | - | -2.838 | - | 1 | - | -164 | - | -1 | - | -1 | - | 115 |
| 2019 | -2.2300 | -2.163 | 2 | 1 | -27 | -125 | -28 | -1 | -26 | -1 | 6 | 62 |
| 2020 | -2.0500 | -2.352 | 1 | 0.09 | -49 | -136 | -53 | 0.09 | -53 | 0.09 | 13 | 5 |
| 2022 | -2.7800 | -3.164 | 1 | 4 | -106 | -183 | -107 | -4 | -108 | -4 | 24 | 265 |
| 2023 | -3.0800 | -3.632 | 4 | 4 | -159 | -212 | -167 | -4 | -169 | -4 | 42 | 263 |
| 2024 | - | -3.695 | - | 1 | - | -214 | - | -1 | - | -1 | - | 124 |
| 2025 | - | -3.858 | - | 11 | - | -209 | - | -11 | - | -11 | - | 737 |
| 2026 | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F71/td> | - | 2.F71 | - | 2.F71 |
| 2027 | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F81/td> | - | 1.F81 | - | 1.F81 |
| 2028 | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F91/td> | - | 0.F91 | - | 0.F91 |